6-Amino-N-(4-methyl-1,3-thiazol-2-yl)-8-(trifluoromethyl)-4-thia-2-azatricyclo[7.3.0.03,7]dodeca-1(9),2,5,7-tetraene-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 6-Amino-N-(4-methyl-1,3-thiazol-2-yl)-8-(trifluoromethyl)-4-thia-2-azatricyclo[7.3.0.03,7]dodeca-1(9),2,5,7-tetraene-5-carboxamide
• 化学式: C₁₆H₁₃F₃N₄OS₂
• 分子量: 398.4
• InChiKey: PPKYBLJPUZGDGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• METHODS TO IDENTIFY INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE
  申请人：Koong Albert C.

  公开号：US20090291857A1

  公开（公告）日：2009-11-26

  Methods for identifying compounds that are inhibitors of the unfolded protein response are provided. In particular, the methods identify compounds that inhibit the activity of IRE1.
• INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE AND METHODS FOR THEIR USE
  申请人：Koong Albert C.

  公开号：US20090312362A1

  公开（公告）日：2009-12-17

  Compounds that are inhibitors of the unfolded protein response and endonuclease IRE1 are provided, together with compositions comprising such compounds, and methods for their use in the treatment of various disorders, such as cancer, autoimmune disorders, and diabetes. Also provided are packaged pharmaceuticals comprising these compositions. The compositions may be administered in combination with another therapeutic agent.
• US8372861B2
  申请人：——

  公开号：US8372861B2

  公开（公告）日：2013-02-12
• [EN] INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE LA REPONSE AUX PROTEINES NON DEPLIEES ET PROCEDES D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2007101224A2

  公开（公告）日：2007-09-07

  [EN] Compounds that are inhibitors of the unfolded protein response and endonuclease IRE1 are provided, together with compositions comprising such compounds, and methods for their use in the treatment of various disorders, such as cancer, autoimmune disorders, and diabetes. Also provided are packaged pharmaceuticals comprising these compositions. The compositions may be administered in combination with another therapeutic agent.
  [FR] L'invention porte sur des inhibiteurs de la réponse aux protéines dépliées et sur l'endonucléase IRE1, ainsi que sur des compositions renfermant lesdits composés, et sur des procédés associés utilisés pour traiter diverses pathologies, telles que le cancer, les maladies autoimmunes et le diabète. L'invention porte également sur des produits pharmaceutiques conditionnés renfermant lesdites compositions. Ces compositions peuvent être administrées en combinaison avec un autre agent thérapeutique.